All In Biotech

Drug Trial Radar · NCT07175220

Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects

A Multicenter, Open Label Phase II Clinical Study on the Safety, Tolerability, and Efficacy of SHR2554 Tablets in Combination With Other Anti-tumor Treatments in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Nov 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Oct 9, 2025

Primary completion

Oct 2028

Study completion Oct 2028

Sponsor

Sponsor type
Industry
First posted
Sep 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluate the safety, tolerability, and objective response rate (ORR) of SHR2554 tablets in combination with other anti-tumor treatments in subjects with locally advanced or metastatic non-small cell lung cancer

Conditions

  • Locally Advanced or Metastatic Non-small Cell Lung Cancer

Interventions

  • SHR2554; SHR-A2102Drug

    SHR2554 tablets combined with SHR-A2102 for injection, with a cycle of 21 days

  • SHR2554; AdabelimumabDrug

    SHR2554 tablets combined with Adabelimumab, with a cycle of 21 days

  • SHR2554; SHR-1701Drug

    SHR2554 tablets combined with SHR-1701 injection, with a cycle of 21 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DLTTime frame: 21days after the first administration of each subject
  2. AETime frame: from Day1 to 30 days after last dose
  3. Incidence and severity of serious adverse events (SAE)Time frame: from Day1 to 30 days after last dose
  4. ORRTime frame: from first dose to disease progression or death, whichever comes first, up to 3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.